More on the Tax-Cuts-and-Medicaid-Cuts Bill, Including an Apex Analysis of a Biotech-Boosting R&D Tax Provision
Shares:
Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv
I’ve been on the record for a while now arguing that the conversation around obesity medicines ought not be a debate about whether the medicines are “worth it” -- it
On Thursday, I said that Cost Curve would be off until Monday “unless someone misbehaves.” I don’t know why I put that evil on myself. Because, sure enough, someone misbehaved.